Fatih Mehmet Uckun

Fatih Mehmet Uckun's AcademicInfluence.com Rankings

Fatih Mehmet Uckun

Engineering

#3971

World Rank

#5119

Historical Rank

Biomedical Engineering

#220

World Rank

#227

Historical Rank

engineering Degrees

Fatih Mehmet Uckun

Philosophy

#5663

World Rank

#8531

Historical Rank

Logic

#2904

World Rank

#3976

Historical Rank

philosophy Degrees

Download Badge

Engineering
Philosophy

Fatih Mehmet Uckun's Degrees

PhD Biomedical Engineering University of California, Berkeley
Doctorate Medicine University of California, San Francisco

Why Is Fatih Mehmet Uckun Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Fatih Mehmet Uckun's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. (1996) (881)
Reactive oxygen intermediates activate NF-kappa B in a tyrosine kinase- dependent mechanism and in combination with vanadate activate the p56lck and p59fyn tyrosine kinases in human lymphocytes (1993) (262)
Dimeric drug polymeric nanoparticles with exceptionally high drug loading and quantitative loading efficiency. (2015) (257)
Regulation of human B-cell ontogeny. (1990) (255)
Early response to therapy and outcome in childhood acute lymphoblastic leukemia (1997) (226)
Expression of dominant-negative and mutant isoforms of the antileukemic transcription factor Ikaros in infant acute lymphoblastic leukemia. (1999) (220)
Ionizing radiation stimulates unidentified tyrosine-specific protein kinases in human B-lymphocyte precursors, triggering apoptosis and clonogenic cell death. (1992) (190)
Inhibition of HIV replication by pokeweed antiviral protein targeted to CD4+ cells by monoclonal antibodies (1990) (189)
Treatment outcome and prognostic factors for infants with acute lymphoblastic leukemia treated on two consecutive trials of the Children's Cancer Group. (1999) (185)
Rational Design and Synthesis of a Novel Anti-leukemic Agent Targeting Bruton′s Tyrosine Kinase (BTK), LFM-A13 [α-Cyano-β-Hydroxy-β-Methyl-N-(2,5-Dibromophenyl)Propenamide]* (1999) (176)
BTK as a Mediator of Radiation-Induced Apoptosis in DT-40 Lymphoma B Cells (1996) (173)
Structure-based design of specific inhibitors of Janus kinase 3 as apoptosis-inducing antileukemic agents. (1999) (171)
Biology and treatment of childhood T-lineage acute lymphoblastic leukemia. (1998) (170)
Detailed studies on expression and function of CD19 surface determinant by using B43 monoclonal antibody and the clinical potential of anti-CD19 immunotoxins. (1988) (168)
Clinical development of microbicides for the prevention of HIV infection. (2004) (163)
Clinical significance of translocation t(1;19) in childhood acute lymphoblastic leukemia in the context of contemporary therapies: a report from the Children's Cancer Group. (1998) (150)
Size-dependent tumor penetration and in vivo efficacy of monodisperse drug-silica nanoconjugates. (2013) (144)
Expression of aberrantly spliced oncogenic ikaros isoforms in childhood acute lymphoblastic leukemia. (1999) (135)
Bruton’s Tyrosine Kinase as an Inhibitor of the Fas/CD95 Death-inducing Signaling Complex* (1999) (134)
Stimulation of protein tyrosine phosphorylation, phosphoinositide turnover, and multiple previously unidentified serine/threonine-specific protein kinases by the Pan-B-cell receptor CD40/Bp50 at discrete developmental stages of human B-cell ontogeny. (1991) (133)
Tyrosine phosphorylation is a mandatory proximal step in radiation-induced activation of the protein kinase C signaling pathway in human B-lymphocyte precursors (1993) (133)
Clinical significance of Philadelphia chromosome positive pediatric acute lymphoblastic leukemia in the context of contemporary intensive therapies (1998) (127)
Clinical significance of MLL-AF4 fusion transcript expression in the absence of a cytogenetically detectable t(4;11)(q21;q23) chromosomal translocation. (1998) (125)
Effect of stereochemistry on the anti-HIV activity of chiral thiourea compounds. (2004) (124)
Clinical features and treatment outcome of children with myeloid antigen positive acute lymphoblastic leukemia: a report from the Children's Cancer Group. (1997) (121)
Exposure of B-lineage Lymphoid Cells to Low Energy Electromagnetic Fields Stimulates Lyn Kinase (*) (1995) (119)
Signal transduction through the CD19 receptor during discrete developmental stages of human B-cell ontogeny. (1993) (116)
Immunobiologic differences between normal and leukemic human B-cell precursors. (1988) (116)
IGF1 Receptor Targeted Theranostic Nanoparticles for Targeted and Image-Guided Therapy of Pancreatic Cancer. (2015) (113)
Pokeweed antiviral protein: ribosome inactivation and therapeutic applications. (1992) (107)
Clinical features and treatment outcome of childhood T-lineage acute lymphoblastic leukemia according to the apparent maturational stage of T-lineage leukemic blasts: a Children's Cancer Group study. (1997) (103)
Detailed Studies on Expression and Function of CD19 Surface Determinant by Using B43 Monoclonal Antibody and the Clinical Potential of Anti-CD19 Immunotoxins (1988) (103)
Synthesis, X-ray structure, and anti-leukemic activity of oxovanadium(IV) complexes. (2000) (102)
Dawn of non-nucleoside inhibitor-based anti-HIV microbicides. (2006) (102)
Pretransplantation burden of leukemic progenitor cells as a predictor of relapse after bone marrow transplantation for acute lymphoblastic leukemia. (1993) (100)
Innovative treatment programs against cancer: II. nuclear factor-κB (NF-κB) as a molecular target (1999) (100)
STAT3 is a substrate of SYK tyrosine kinase in B-lineage leukemia/lymphoma cells exposed to oxidative stress (2010) (97)
Leukemic cell growth in SCID mice as a predictor of relapse in high-risk B-lineage acute lymphoblastic leukemia. (1995) (97)
In vivo radioprotective effects of recombinant human granulocyte colony-stimulating factor in lethally irradiated mice. (1990) (96)
Crystal Structure of Bruton's Tyrosine Kinase Domain Suggests a Novel Pathway for Activation and Provides Insights into the Molecular Basis of X-linked Agammaglobulinemia* (2001) (95)
Suppression of Hepatic Inflammation via Systemic siRNA Delivery by Membrane-Disruptive and Endosomolytic Helical Polypeptide Hybrid Nanoparticles. (2016) (92)
Plant resistance to fungal infection induced by nontoxic pokeweed antiviral protein mutants (1997) (89)
Metvan: a novel oxovanadium(IV) complex with broad spectrum anticancer activity (2002) (88)
Biased distribution of chromosomal breakpoints involving the MLL gene in infants versus children and adults with t(4;11) ALL (2001) (88)
In vivo toxicity, pharmacokinetics, and anticancer activity of Genistein linked to recombinant human epidermal growth factor. (1998) (84)
Treatment of therapy-refractory B-lineage acute lymphoblastic leukemia with an apoptosis-inducing CD19-directed tyrosine kinase inhibitor. (1999) (84)
In vivo efficacy of B43 (anti-CD19)-pokeweed antiviral protein immunotoxin against human pre-B cell acute lymphoblastic leukemia in mice with severe combined immunodeficiency. (1992) (84)
Pokeweed antiviral protein isoforms PAP-I, PAP-II, and PAP-III depurinate RNA of human immunodeficiency virus (HIV)-1. (1999) (83)
Use of multiple T cell-directed intact ricin immunotoxins for autologous bone marrow transplantation. (1985) (82)
Bis(4,7-dimethyl-1,10-phenanthroline) sulfatooxovanadium(IV) as a novel apoptosis-inducing anticancer agent. (2000) (81)
Supramolecular self-assembled nanoparticles mediate oral delivery of therapeutic TNF-α siRNA against systemic inflammation. (2013) (81)
Increased efficiency in selective elimination of leukemia cells by a combination of a stable derivative of cyclophosphamide and a human B-cell-specific immunotoxin containing pokeweed antiviral protein. (1985) (80)
Rational design and synthesis of phenethyl-5-bromopyridyl thiourea derivatives as potent non-nucleoside inhibitors of HIV reverse transcriptase (1998) (77)
Leukemic B-cell precursors express functional receptors for human interleukin-3. (1989) (77)
Bruton's tyrosine kinase (BTK) as a dual-function regulator of apoptosis. (1998) (77)
Interleukin 7 receptor ligation stimulates tyrosine phosphorylation, inositol phospholipid turnover, and clonal proliferation of human B-cell precursors. (1991) (76)
Effective immunochemotherapy of CALLA+C mu+ human pre-B acute lymphoblastic leukemia in mice with severe combined immunodeficiency using B43 (anti-CD19) pokeweed antiviral protein immunotoxin plus cyclophosphamide. (1992) (75)
Effects of recombinant growth factors on radiation survival of human bone marrow progenitor cells. (1989) (75)
TXU (Anti-CD7)-Pokeweed Antiviral Protein as a Potent Inhibitor of Human Immunodeficiency Virus (1998) (75)
Cytotoxic activity of epidermal growth factor-genistein against breast cancer cells. (1998) (74)
Combined ex vivo treatment with immunotoxins and mafosfamid: a novel immunochemotherapeutic approach for elimination of neoplastic T cells from autologous marrow grafts. (1985) (74)
Severe combined immunodeficient mouse models of human leukemia. (1996) (74)
Targeting Janus Kinase 3 in Mast Cells Prevents Immediate Hypersensitivity Reactions and Anaphylaxis* (1999) (71)
Improved clinical outcome for children with T-lineage acute lymphoblastic leukemia after contemporary chemotherapy: a Children's Cancer Group Study. (1996) (71)
Transcription Factor STAT5A Is a Substrate of Bruton's Tyrosine Kinase in B Cells* (2001) (71)
Immunotoxin-mediated elimination of clonogenic tumor cells in the presence of human bone marrow. (1985) (70)
Stimulation of Src Family Protein-tyrosine Kinases as a Proximal and Mandatory Step for SYK Kinase-dependent Phospholipase Cγ2 Activation in Lymphoma B Cells Exposed to Low Energy Electromagnetic Fields* (1998) (70)
CD45 cross-linking regulates phospholipase C activation and tyrosine phosphorylation of specific substrates in CD3/Ti-stimulated T cells. (1991) (69)
Comparative analysis of the in vivo radioprotective effects of recombinant granulocyte colony-stimulating factor (G-CSF), recombinant granulocyte-macrophage CSF, and their combination. (1991) (69)
Spleen tyrosine kinase (Syk) deficiency in childhood pro-B cell acute lymphoblastic leukemia (2001) (69)
Inducing apoptosis in chemotherapy‐resistant B‐lineage acute lymphoblastic leukaemia cells by targeting HSPA5, a master regulator of the anti‐apoptotic unfolded protein response signalling network (2011) (69)
Targeting JAK3 with JANEX-1 for prevention of autoimmune type 1 diabetes in NOD mice. (2003) (67)
INTERLEUKIN 2 IMMEDIATELY AFTER AUTOLOGOUS BONE MARROW TRANSPLANTATION FOR ACUTE LYMPHOBLASTIC LEUKEMIA–A PHASE I STUDY (1993) (65)
Cellular Expression of Antiapoptotic BCL-2 Oncoprotein in Newly Diagnosed Childhood Acute Lymphoblastic Leukemia: A Children's Cancer Group Study (1997) (65)
Treatment of patients with acute lymphoblastic leukemia with bulky extramedullary disease and T‐cell phenotype or other poor prognostic features (1998) (63)
Molecular genotoxicity profiles of apoptosis-inducing vanadocene complexes. (1999) (63)
Anti-HIV activity of aromatic and heterocyclic thiazolyl thiourea compounds. (2001) (63)
Apoptosis-inducing vanadocene compounds against human testicular cancer. (2000) (63)
Bis(4,7-dimethyl-1,10-phenanthroline) sulfatooxovanadium(I.V.) as a novel antileukemic agent with matrix metalloproteinase inhibitory activity. (2001) (63)
Novel Thiourea Compounds as Dual-Function Microbicides (2000) (62)
Autologous bone marrow transplantation in high-risk remission B-lineage acute lymphoblastic leukemia using a cocktail of three monoclonal antibodies (BA-1/CD24, BA-2/CD9, and BA-3/CD10) plus complement and 4-hydroperoxycyclophosphamide for ex vivo bone marrow purging. (1992) (62)
Structure-based design of a novel synthetic spiroketal pyran as a pharmacophore for the marine natural product spongistatin 1. (2000) (62)
Targeting Janus kinase 3 to attenuate the severity of acute graft-versus-host disease across the major histocompatibility barrier in mice. (2001) (61)
Role of Tyrosine Kinases in Induction of the c-junProto-oncogene in Irradiated B-lineage Lymphoid Cells* (1998) (61)
Anti-breast cancer activity of LFM-A13, a potent inhibitor of Polo-like kinase (PLK). (2007) (59)
Isolation and characterization of pokeweed antiviral protein mutations in Saccharomyces cerevisiae: identification of residues important for toxicity. (1995) (59)
Structure-based drug design of non-nucleoside inhibitors for wild-type and drug-resistant HIV reverse transcriptase. (2000) (59)
Role of a JAK3-dependent Biochemical Signaling Pathway in Platelet Activation and Aggregation* (2001) (58)
Serine phosphorylation by SYK is critical for nuclear localization and transcription factor function of Ikaros (2012) (56)
Expression of TEL-AML1 Fusion Transcripts and Response to Induction Therapy in Standard Risk Acute Lymphoblastic Leukemia (2001) (56)
Establishment of a human t(4;11) leukemia in severe combined immunodeficient mice and successful treatment using anti-CD19 (B43)-pokeweed antiviral protein immunotoxin. (1992) (56)
Interleukin 7 receptor engagement stimulates tyrosine phosphorylation, inositol phospholipid turnover, proliferation, and selective differentiation to the CD4 lineage by human fetal thymocytes. (1991) (56)
Ultraviolet radiation rapidly induces tyrosine phosphorylation and calcium signaling in lymphocytes. (1993) (55)
Vanadocenes as potent anti-proliferative agents disrupting mitotic spindle formation in cancer cells (2001) (55)
Prophylactic contraceptives for HIV/AIDS. (1999) (55)
Potent dual anti-HIV and spermicidal activities of novel oxovanadium(V) complexes with thiourea non-nucleoside inhibitors of HIV-1 reverse transcriptase. (2003) (54)
A Study of the Potential of the Pig as a Model for the Vaginal Irritancy of Benzalkonium Chloride in Comparison to the Nonirritant Microbicide PHI-443 and the Spermicide Vanadocene Dithiocarbamate (2005) (54)
Calphostin C triggers calcium-dependent apoptosis in human acute lymphoblastic leukemia cells. (1998) (53)
Allogeneic bone marrow transplantation for acute lymphoblastic leukaemia: risk factors and clinical outcome (1994) (52)
Structure-based design of N-[2-(1-piperidinylethyl)]-N'-[2-(5-bromopyridyl)]-thiourea and N-[2-(1-piperazinylethyl)]-N'-[2-(5-bromopyridyl)]-thiourea as potent non-nucleoside inhibitors of HIV-1 reverse transcriptase. (1998) (52)
Aryl phosphate derivatives of bromo-methoxy-azidothymidine are dual-function spermicides with potent anti-human immunodeficiency virus. (1998) (51)
In Vivo Toxicity, Pharmacokinetics, and Anti-Human Immunodeficiency Virus Activity of Stavudine-5′-(p-Bromophenyl Methoxyalaninyl Phosphate) (Stampidine) in Mice (2002) (51)
IMMUNOTOXINS FOR THE TREATMENT OF LEUKAEMIA (1993) (51)
CD22 EXON 12 deletion as a pathogenic mechanism of human B-precursor leukemia (2010) (50)
In vivo antitumor activity of bis(4,7-dimethyl-1,10-phenanthroline) sulfatooxovanadium(IV) (METVAN [VO(SO4)(Me2-Phen)2]). (2001) (50)
Biotargeted nanomedicines for cancer: six tenets before you begin. (2013) (50)
Rational design of N-[2-(2,5-dimethoxyphenylethyl)]-N'-[2-(5-bromopyridyl)]-thiourea (HI-236) as a potent non-nucleoside inhibitor of drug-resistant human immunodeficiency virus. (1999) (49)
B-cell growth factor receptor expression and B-cell growth factor response of leukemic B cell precursors and B lineage lymphoid progenitor cells (1987) (48)
In vivo toxicity and pharmacokinetic features of the janus kinase 3 inhibitor WHI-P131 [4-(4'hydroxyphenyl)-amino-6,7- dimethoxyquinazoline. (1999) (47)
Stampidine Is a Potent Inhibitor of Zidovudine- and Nucleoside Analog Reverse Transcriptase Inhibitor-Resistant Primary Clinical Human Immunodeficiency Virus Type 1 Isolates with Thymidine Analog Mutations (2002) (46)
Calpain inhibitor II induces caspase-dependent apoptosis in human acute lymphoblastic leukemia and non-Hodgkin's lymphoma cells as well as some solid tumor cells. (2000) (46)
Role of tyrosine phosphorylation in radiation-induced activation of c-jun protooncogene in human lymphohematopoietic precursor cells. (1993) (46)
Enhancing effects of a mono-bromo substitution at the para position of the phenyl moiety on the metabolism and anti-HIV activity of d4T-phenyl methoxyalaninyl phosphate derivatives. (1998) (46)
N'-[2-(2-thiophene)ethyl]-N'-[2-(5-bromopyridyl)] thiourea as a potent inhibitor of NNI-resistant and multidrug-resistant human immunodeficiency virus-1. (1999) (45)
X‐ray crystallographic analysis of the structural basis for the interactions of pokeweed antiviral protein with its active site inhibitor and ribosomal RNA substrate analogs (1999) (45)
Treatment of allergic asthma by targeting janus kinase 3-dependent leukotriene synthesis in mast cells with 4-(3', 5'-dibromo-4'-hydroxyphenyl)amino-6,7-dimethoxyquinazoline (WHI-P97). (2000) (45)
Human t(1;19)(q23;p13) pre-B acute lymphoblastic leukemia in mice with severe combined immunodeficiency. (1993) (45)
Structural Requirements for Potent Human Spermicidal Activity of Dual-Function Aryl Phosphate Derivative of Bromo-Methoxy Zidovudine (Compound WHI-07)1 (2000) (44)
In Vivo Antiretroviral Activity of Stampidine in Chronically Feline Immunodeficiency Virus-Infected Cats (2003) (44)
Redox-responsive, reversibly-crosslinked thiolated cationic helical polypeptides for efficient siRNA encapsulation and delivery. (2015) (44)
Poor treatment outcome of Philadelphia chromosome-positive pediatric acute lymphoblastic leukemia despite intensive chemotherapy. (1999) (44)
Structure-Based Design of Novel Dihydroalkoxybenzyloxopyrimidine Derivatives as Potent Nonnucleoside Inhibitors of the Human Immunodeficiency Virus Reverse Transcriptase (1998) (43)
Antioxidant function of phenethyl-5-bromo-pyridyl thiourea compounds with potent anti-HIV activity. (2000) (43)
Toxicity, biological activity, and pharmacokinetics of TXU (anti-CD7)-pokeweed antiviral protein in chimpanzees and adult patients infected with human immunodeficiency virus. (1999) (43)
Janus kinase 3 inhibitor WHI-P131/JANEX-1 prevents graft-versus-host disease but spares the graft-versus-leukemia function of the bone marrow allografts in a murine bone marrow transplantation model. (2002) (43)
Reduced Folate Carrier and Dihydrofolate Reductase Expression in Acute Lymphocytic Leukemia May Predict Outcome: A Children's Cancer Group Study (2003) (42)
Electromagnetic Field-induced Stimulation of Bruton’s Tyrosine Kinase* (1998) (41)
Stereochemistry of halopyridyl and thiazolyl thiourea compounds is a major determinant of their potency as nonnucleoside inhibitors of HIV-1 reverse transcriptase. (2000) (40)
Antigen-independent regulation of cytoplasmic calcium in B cells with a 12-kDa B-cell growth factor and anti-CD19. (1988) (40)
4-(3'-Bromo-4'hydroxylphenyl)-amino-6,7-dimethoxyquinazoline: a novel quinazoline derivative with potent cytotoxic activity against human glioblastoma cells. (1998) (40)
Role of Janus kinase 3 in mast cell-mediated innate immunity against gram-negative bacteria. (2001) (39)
Ten-year survival of children with acute lymphoblastic leukemia: A report from the Children's Oncology Group (2008) (39)
Immunotoxins show rapid entry of diphtheria toxin but not ricin via the T3 antigen. (1986) (39)
Clinical Significance of Deletions of Chromosome Arm 6q in Childhood Acute Lymphoblastic Leukemia: A Report from the Children's Cancer Group (2000) (39)
Role of STAT6 in IgE Receptor/FcεRI-Mediated Late Phase Allergic Responses of Mast Cells (2002) (39)
Innovative treatment programs against cancer. I. Ras oncoprotein as a molecular target. (1998) (38)
Novel Bruton’s tyrosine kinase inhibitors currently in development (2013) (37)
Deguanylation of human immunodeficiency virus (HIV-1) RNA by recombinant pokeweed antiviral protein. (1999) (37)
High-level expression and purification of biologically active recombinant pokeweed antiviral protein. (1999) (37)
N-[2-(1-cyclohexenyl)ethyl]-N'-[2-(5-bromopyridyl)]-thiourea and N'-[2-(1-cyclohexenyl)ethyl]-N'-[2-(5-chloropyridyl)]-thiourea as potent inhibitors of multidrug-resistant human immunodeficiency virus-1. (1999) (37)
Combined immunochemotherapy of human solid tumors in nude mice. (1987) (37)
Highly sensitive liquid chromatography-electrospray mass spectrometry (LC-MS) method for the determination of etoposide levels in human serum and plasma. (2000) (36)
Synthesis and Structure of Bis(pi-cyclopentadienyl)vanadium(IV) 1,10-Phenanthroline and 2,2'-Bipyridine Compounds and Their Interactions with Artificial Membranes. (1999) (36)
Metabolism of stavudine-5'-[p-bromophenyl methoxyalaninyl phosphate], stampidine, in mice, dogs, and cats. (2002) (36)
Spermicidal activity of chelated complexes of bis(cyclopentadienyl)vanadium(IV). (1998) (36)
Thrombopoietin induces p-selectin expression on platelets and subsequent platelet/leukocyte interactions. (2002) (36)
Enhanced transmembrane signalling activity of monoclonal antibody heteroconjugates suggests molecular interactions between receptors on the T cell surface. (1989) (35)
Genetic and biochemical evidence for a critical role of Janus kinase (JAK)-3 in mast cell-mediated type I hypersensitivity reactions. (1999) (34)
Physical and Functional Interactions between Lyn and p34 Kinases in Irradiated Human B-cell Precursors (*) (1996) (34)
Human t(4;11)(q21;q23) acute lymphoblastic leukemia in mice with severe combined immunodeficiency. (1994) (34)
In Vivo Pharmacokinetic Features, Toxicity Profile, and Chemosensitizing Activity of α-Cyano-β-hydroxy-β- methyl-N-(2,5-dibromophenyl)propenamide (LFM-A13), a Novel Antileukemic Agent Targeting Bruton’s Tyrosine Kinase (2002) (34)
Defective Expression of Bruton's Tyrosine Kinase in Acute Lymphoblastic Leukemia (2003) (34)
Prognostic significance of the CD10+CD19+CD34+ B-progenitor immunophenotype in children with acute lymphoblastic leukemia: a report from the Children's Cancer Group. (1997) (34)
In vivo pharmacokinetics and metabolism of anti-human immunodeficiency virus agent D4T-5'-[p-bromophenyl methoxyalaninyl phosphate] (SAMPIDINE) in mice. (2001) (34)
Ex vivo elimination of lymphoblastic leukemia cells from human marrow by mafosfamid. (1985) (33)
Structure-Based Design of Non-Nucleoside Reverse Transcriptase Inhibitors of Drug-Resistant Human Immunodeficiency Virus (1999) (33)
Studies in Humans on the Mechanism of Potent Spermicidal and Apoptosis-Inducing Activities of Vanadocene Complexes (2000) (33)
Stereocontrolled synthesis of a novel pharmacophore of the tubulin-depolymerizing marine natural product spongistatin (2000) (33)
Differential substrate recognition capabilities of Janus family protein tyrosine kinases within the interleukin 2 receptor (IL2R) system: Jak3 as a potential molecular target for treatment of leukemias with a hyperactive Jak-Stat signaling machinery. (1999) (33)
Targeting SYK kinase‐dependent anti‐apoptotic resistance pathway in B‐lineage acute lymphoblastic leukaemia (ALL) cells with a potent SYK inhibitory pentapeptide mimic (2010) (32)
Nanoscale liposomal formulation of a SYK P-site inhibitor against B-precursor leukemia. (2013) (32)
Human sperm immobilizing activity of aminophenyl arsenic acid and its N-substituted quinazoline, pyrimidine, and purine derivatives: protective effect of glutathione. (2002) (32)
5-Alkyl-2-[(methylthiomethyl)thio]-6-(benzyl)-pyrimidin-4-(1H)-ones as potent non-nucleoside reverse transcriptase inhibitors of S-DABO series. (1998) (32)
Intrinsic radiation resistance of primary clonogenic blasts from children with newly diagnosed B-cell precursor acute lymphoblastic leukemia. (1993) (32)
In vivo pharmacokinetic features, toxicity profile, and chemosensitizing activity of alpha-cyano-beta-hydroxy-beta- methyl-N-(2,5-dibromophenyl)propenamide (LFM-A13), a novel antileukemic agent targeting Bruton's tyrosine kinase. (2002) (32)
Targeting Spleen Tyrosine Kinase (Syk) for Treatment of Human Disease (2012) (31)
Induction of apoptosis in multidrug-resistant and radiation-resistant acute myeloid leukemia cells by a recombinant fusion toxin directed against the human granulocyte macrophage colony-stimulating factor receptor. (1997) (31)
Targeting Mast Cells in Endometriosis with Janus Kinase 3 Inhibitor, JANEX‐1 (2007) (31)
Increased hydroxyl radical production and apoptosis in PC12 neuron cells expressing the gain-of-function mutant G93A SOD1 gene. (1999) (31)
Pre-clinical safety evaluation of novel nucleoside analogue-based dual-function microbicides (WHI-05 and WHI-07). (2002) (31)
Development and characterization of three recombinant single chain antibody fragments (scFvs) directed against the CD19 antigen. (1995) (30)
Inhibition of human glioblastoma cell adhesion and invasion by 4-(4'-hydroxylphenyl)-amino-6,7-dimethoxyquinazoline (WHI-P131) and 4-(3'-bromo-4'-hydroxylphenyl)-amino-6,7-dimethoxyquinazoline (WHI-P154). (1998) (30)
Structural and biological characterization of a novel spermicidal vanadium(IV) complex: bis(pi-cyclopentadienyl)-N,N-diethyl dithiocarbamato vanadium(IV) tetrafluoro borate, [VCp2(DeDtc)](BF4). (1998) (30)
Antiretroviral Spermicide WHI-07 Prevents Vaginal and Rectal Transmission of Feline Immunodeficiency Virus in Domestic Cats (2004) (30)
Regiospecific synthesis, X-ray crystal structure and biological activities of 5-bromothiophenethyl thioureas (2001) (30)
Active center cleft residues of pokeweed antiviral protein mediate its high-affinity binding to the ribosomal protein L3. (2001) (29)
G19.4(alpha CD3) x B43(alpha CD19) monoclonal antibody heteroconjugate triggers CD19 antigen-specific lysis of t(4;11) acute lymphoblastic leukemia cells by activated CD3 antigen-positive cytotoxic T cells. (1992) (29)
Dual targeting of Bruton's tyrosine kinase and Janus kinase 3 with rationally designed inhibitors prevents graft‐versus‐host disease (GVHD) in a murine allogeneic bone marrow transplantation model (2004) (29)
Abnormalities of chromosome bands 15q13‐15 in childhood acute lymphoblastic leukemia (2002) (28)
Repurposing Anti-Malaria Phytomedicine Artemisinin as a COVID-19 Drug (2021) (28)
Spleen tyrosine kinase as a molecular target for treatment of leukemias and lymphomas (2010) (28)
Leukemic B-cell precursors constitutively express functional receptors for human interleukin-1. (1989) (28)
B-cell growth factor receptor expression and B-cell growth factor response of leukemic B cell precursors and B lineage lymphoid progenitor cells. (1987) (28)
B lymphocyte regulation of human hematopoiesis. (1985) (27)
Bruton's tyrosine kinase prevents activation of the anti‐apoptotic transcription factor STAT3 and promotes apoptosis in neoplastic B‐cells and B‐cell precursors exposed to oxidative stress (2007) (27)
CD2 antigen expression on leukemic cells as a predictor of event-free survival after chemotherapy for T-lineage acute lymphoblastic leukemia: a Children's Cancer Group study. (1996) (27)
Modeling and Alanine Scanning Mutagenesis Studies of Recombinant Pokeweed Antiviral Protein* (2000) (27)
Toxicity and Pharmacokinetics of Stampidine in Mice and Rats (2003) (27)
Gene expression profiles of infant acute lymphoblastic leukaemia and its prognostically distinct subsets (2010) (27)
Rational design of potent and selective EGFR tyrosine kinase inhibitors as anticancer agents. (2001) (26)
Vaginal microbicides and their delivery platforms (2014) (26)
X-ray structure, solution properties, and biological activity profile of vanadocene(IV) acetylacetonate complex, [VCp2(acac)](CF3SO3): a dual-function anti-cancer agent with anti-angiogenic and anti-mitotic properties (2001) (26)
Lack of CD24 antigen expression in B-lineage acute lymphoblastic leukemia is associated with intrinsic radiation resistance of primary clonogenic blasts. (1993) (26)
Bone marrow transplantation for acute lymphocytic leukemia utilizing total body irradiation followed by high doses of cytosine arabinoside: lack of superiority over cyclophosphamide-containing conditioning regimens. (1990) (26)
Treatment of Post-Bone Marrow Transplant Acute Graft-Versus-Host Disease with a Rationally Designed JAK3 Inhibitor (2002) (26)
Clinical Pharmacokinetics of the CD19 Receptor‐Directed Tyrosine Kinase Inhibitor B43‐Genistein in Patients with B‐Lineage Lymphoid Malignancies (1999) (26)
Bruton's tyrosine kinase as a molecular target in treatment of leukemias and lymphomas as well as inflammatory disorders and autoimmunity (2010) (26)
Structure-based design of novel anticancer agents. (2001) (25)
Targeting JAK3 tyrosine kinase-linked signal transduction pathways with rationally-designed inhibitors. (2007) (25)
Pharmacokinetic Features and Metabolism of Calphostin C, A Naturally Occurring Perylenequinone with Antileukemic Activity (1999) (25)
Donor-specific unmodified bone marrow transfusion does not facilitate intestinal engraftment after bowel transplantation in a porcine model. (1997) (25)
In vitro and in vivo cytotoxicity of an anti-osteosarcoma immunotoxin containing pokeweed antiviral protein. (1995) (25)
Chemosensitivity of TEL-AML1 Fusion Transcript Positive Acute Lymphoblastic Leukemia Cells (2001) (25)
Immunotoxins for treatment of leukemia and lymphoma. (1995) (25)
Preclinical Evaluation of a Dual-Acting Microbicidal Prodrug WHI-07 in Combination with Vanadocene Dithiocarbamate in the Female Reproductive Tract of Rabbit, Pig, and Cat (2007) (25)
CD4 and CD8 are positive regulators of T cell receptor signal transduction in early T cell differentiation. (1991) (25)
Novel broad-spectrum thiourea non-nucleoside inhibitors for the prevention of mucosal HIV transmission. (2006) (25)
GM-144, a novel lipophilic vaginal contraceptive gel-microemulsion (2001) (24)
Cellular expression of antiapoptotic BCL-2 oncoprotein in newly diagnosed childhood acute lymphoblastic leukemia: a Children's Cancer Group Study. (1997) (24)
D4T-5'-[p-bromophenyl methoxyalaninyl phosphate] as a potent and non-toxic anti-human immunodeficiency virus agent. (1998) (24)
Innovative treatment programs against cancer: II. Nuclear factor-kappaB (NF-kappaB) as a molecular target. (1999) (24)
Recipient preconditioning and donor-specific bone marrow infusion in a pig model of total bowel transplantation. (1997) (24)
High-performance liquid chromatographic methods for the determination of topoisomerase II inhibitors. (2001) (24)
CD2 antigen expression on leukemic cells as a predictor of event-free survival after chemotherapy for T-lineage acute lymphoblastic leukemia: a Children's Cancer Group study (1996) (24)
CD44 Mediated Nonviral Gene Delivery into Human Embryonic Stem Cells via Hyaluronic-Acid-Coated Nanoparticles. (2016) (24)
Polo‐like‐kinase 1 (PLK1) as a molecular target to overcome SYK‐mediated resistance of B‐lineage acute lymphoblastic leukaemia cells to oxidative stress (2010) (24)
X-ray crystallographic analysis of pokeweed antiviral protein-II after reductive methylation of lysine residues. (2000) (24)
Vinorelbine‐based salvage chemotherapy for therapy‐refractory aggressive leukaemias (2006) (24)
Effects of Aryl Substituents on the Anti-HIV Activity of the Arylphosphoramidate Derivatives of Stavudine (2002) (24)
Novel tight binding PETT, HEPT and DABO-based non-nucleoside inhibitors of HIV-1 reverse transcriptase (2006) (24)
Lack of CD24 antigen expression in B-lineage acute lymphoblastic leukemia is associated with intrinsic radiation resistance of primary clonogenic blasts (1993) (23)
IMMUNOTOXINS FOR EX VIVO MARROW PURGING IN AUTOLOGOUS BONE MARROW TRANSPLANTATION FOR ACUTE NONLYMPHOCYTIC LEUKEMIA (1988) (23)
In vitro Activity of Stampidine against Primary Clinical Human Immunodeficiency Virus Isolates (2004) (23)
Clinical features and treatment outcome of children with biphenotypic CD2+ CD19+ acute lymphoblastic leukemia: a Children's Cancer Group study. (1997) (23)
Rationally designed anti-mitotic agents with pro-apoptotic activity. (2001) (23)
Structure-Based Design and Engineering of a Nontoxic Recombinant Pokeweed Antiviral Protein with Potent Anti-Human Immunodeficiency Virus Activity (2003) (22)
Antibody Responses to COVID-19 Vaccination in Cancer: A Systematic Review (2021) (22)
Regulatory Phosphorylation of Ikaros by Bruton's Tyrosine Kinase (2013) (22)
Chemosensitizing Anti-Cancer Activity of LFM-A13, a Leflunomide Metabolite Analog Targeting Polo-like Kinases (2007) (22)
Mucosal Toxicity Studies of a Gel Formulation of Native Pokeweed Antiviral Protein (2004) (22)
Prognostic significance of cytogenetic abnormalities of chromosome arm 12p in childhood acute lymphoblastic leukemia (2000) (22)
Limitations of the Human‐PBL‐SCID Mouse Model for Vaginal Transmission of HIV‐1 (2007) (22)
Prognostic significance of T-lineage leukemic cell growth in SCID mice: a Children's Cancer Group study. (1998) (22)
Signal Transduction through the 1 Integrin Family Surface Adhesion Molecules VLA-4 and VLA-5 of Human B-cell Precursors Activates CD19 Receptor-associated Protein-tyrosine Kinases (*) (1996) (21)
PHI-443: A Novel Noncontraceptive Broad-Spectrum Anti-Human Immunodeficiency Virus Microbicide1 (2004) (21)
Overcoming the Immunosuppressive Tumor Microenvironment in Multiple Myeloma (2021) (21)
In vivo Anti-Cancer Activity of a Liposomal Nanoparticle Construct of Multifunctional Tyrosine Kinase Inhibitor 4-(4'-Hydroxyphenyl)-Amino-6,7-Dimethoxyquinazoline (2010) (21)
Conceival, a novel noncontraceptive vaginal vehicle for lipophilic microbicides (2005) (21)
EGF-genistein inhibits neointimal hyperplasia after vascular injury in an experimental restenosis model. (2000) (21)
Increased efficacy in selective elimination of leukemic cell line clonogenic cells by a combination of monoclonal antibodies BA-1, BA-2, BA-3 + complement and mafosfamid (ASTA Z 7557). (1986) (21)
COVID-19 pandemic: changes in cancer admissions (2020) (21)
Preclinical and first-in-human phase I clinical evaluation of stampidine, a potent anti-HIV pharmaceutical drug candidate. (2012) (21)
Anticancer activity of synthetic analogues of the phorboxazoles. (2001) (21)
Role of the Leukemia-associated Transcription Factor STAT3 in Platelet Physiology (2002) (21)
CD95 (APO‐1/FAS) deficiency in infant acute lymphoblastic leukemia: detection of novel soluble Fas splice variants (2003) (21)
Lack of adverse effects on fertility of female cd‐1 mice exposed to repetitive intravaginal gel–microemulsion formulation of a dual‐function anti‐HIV agent: aryl phosphate derivative of bromo‐methoxy‐zidovudine (compound WHI‐07) (2001) (21)
Cathepsin Inhibition Induces Apoptotic Death in Human Leukemia and Lymphoma Cells (2000) (21)
Spongistatins as tubulin targeting agents. (2001) (21)
Thymidine Kinase-Independent Intracellular Delivery of Bioactive Nucleotides by Aryl Phosphate Derivatives of Bromo-Methoxy Zidovudine (Compounds WHI-05 and WHI-07) in Normal Human Female Genital Tract Epithelial Cells and Sperm1 (2001) (21)
Structural Requirements for Potent Anti-Human Immunodeficiency Virus (HIV) and Sperm-Immobilizing Activities of Cyclohexenyl Thiourea and Urea Non-Nucleoside Inhibitors of HIV-1 Reverse Transcriptase1 (2002) (20)
Z-Phe-Gly-NHO-Bz, an inhibitor of cysteine cathepsins, induces apoptosis in human cancer cells. (2000) (20)
AZT-5′-(p-Bromophenyl Methoxyalaninyl Phosphate) as a Potent and Non-Toxic Anti-Human Immunodeficiency Virus Agent (1999) (20)
A Phase 1B Clinical Study of Combretastatin A1 Diphosphate (OXi4503) and Cytarabine (ARA-C) in Combination (OXA) for Patients with Relapsed or Refractory Acute Myeloid Leukemia (2019) (20)
Brutons Tyrosine Kinase as a New Therapeutic Target (2007) (20)
Role of STAT6 in IgE receptor/FcepsilonRI-mediated late phase allergic responses of mast cells. (2002) (20)
Substituted heterocyclic thiourea compounds as a new class of anti-allergic agents inhibiting IgE/Fc epsilon RI receptor mediated mast cell leukotriene release. (2003) (20)
Binding Interactions between the Active Center Cleft of Recombinant Pokeweed Antiviral Protein and the α-Sarcin/Ricin Stem Loop of Ribosomal RNA* (2001) (20)
Stereochemical influence on lipase-mediated hydrolysis and biological activity of stampidine and other stavudine phosphoramidates. (2005) (20)
Evaluating dissolution profiles of an anti-HIV agent using ANOVA and non-linear regression models in JMP software. (2003) (20)
A requirement for protein kinase C inhibition for calcium-triggered apoptosis in acute lymphoblastic leukemia cells. (1999) (20)
Bioavailability and Pharmacokinetic Features of Etoposide in Childhood Acute Lymphoblastic Leukemia Patients (2001) (20)
CD22 Exon 12 deletion is a characteristic genetic defect of therapy‐refractory clones in paediatric acute lymphoblastic leukaemia (2012) (20)
JAK3 pathway is constitutively active in B-lineage acute lymphoblastic leukemia (2011) (20)
Tyrosine kinases as new molecular targets in treatment of inflammatory disorders and leukemia. (2004) (20)
The Anti-leukemic Bruto n's Tyrosine Kinase Inhibitor α-cyano-β-hydroxy-β-methyl-N-(2,5-dibromophenyl) Propenamide (LFM-A13) Prevents Fatal Thromboembolism (2003) (20)
Anti-T cell immunotoxins containing pokeweed anti-viral protein: potential purging agents for human autologous bone marrow transplantation. (1985) (20)
Vaginal contraceptive activity of a chelated vanadocene. (2005) (19)
Structural influence on the solid state intermolecular hydrogen bonding of substituted thioureas (2005) (19)
SYK as a New Therapeutic Target in B-Cell Precursor Acute Lymphoblastic Leukemia (2014) (19)
N-[2-(4-Methylphenyl)Ethyl]-N′-[2-(5-Bromopyridyl)]-Thiourea as a Potent Inhibitor of NNRTI-Resistant and Multidrug-Resistant Human Immunodeficiency Virus Type 1 (2000) (19)
Histamine as an Autocrine Regulator of Leukemic Cell Proliferation (2000) (19)
Recombinant human CD19L-sTRAIL effectively targets B cell precursor acute lymphoblastic leukemia. (2015) (19)
Discovery of 2,5-dimethoxy-substituted 5-bromopyridyl thiourea (PHI-236) as a potent broad-spectrum anti-human immunodeficiency virus microbicide. (2005) (19)
High resolution X-ray structure of potent anti-HIV pokeweed antiviral protein-III. (2003) (19)
Development and Evaluation of a Thermoreversible Ovule Formulation of Stampidine, a Novel Nonspermicidal Broad-Spectrum Anti-Human Immunodeficiency Virus Microbicide1 (2003) (19)
Organic phenyl arsonic acid compounds with potent antileukemic activity. (2003) (19)
Induction of aerobic peroxidation of liposomal membranes by bis(cyclopentadienyl)-vanadium(IV) (acetylacetonate) complexes. (2001) (19)
Synthesis of Dual Function (5R,6R)- and (5S,6S)-5-Bromo-6-Methoxy-5,6-Dihydro-AZT-5′-(Para-Bromophenyl Methoxyalaninyl Phosphate) as Novel Spermicidal and Anti-HIV Agents (1999) (19)
Accessory receptors regulate coupling of the T-cell receptor complex to tyrosine kinase activation and mobilization of cytoplasmic calcium in T-lineage acute lymphoblastic leukemia. (1991) (19)
Apoptosis-inducing oxovanadium(IV) complexes of 1,10-phenanthroline against human ovarian cancer (2000) (19)
Effect of stereo and regiochemistry towards wild and multidrug resistant HIV-1 virus: viral potency of chiral PETT derivatives. (2004) (18)
Recurrent or Refractory High-Grade Gliomas Treated by Convection-Enhanced Delivery of a TGFβ2-Targeting RNA Therapeutic: A Post-Hoc Analysis with Long-Term Follow-Up (2019) (18)
The current status of immunotoxins: an overview of experimental and clinical studies as presented at the Third International Symposium on Immunotoxins. (1993) (18)
A recombinant fusion toxin targeted to the granulocyte-macrophage colony-stimulating factor receptor. (1997) (18)
Structural and functional characterization of seven spermicidal vanadium(IV) complexes: potentiation of activity by methyl substitution on the cyclopentadienyl rings. (1999) (18)
Clinical Impact Potential of Supplemental Nutrients as Adjuncts of Therapy in High-Risk COVID-19 for Obese Patients (2020) (18)
Reducing the Fatality Rate of COVID-19 by Applying Clinical Insights From Immuno-Oncology and Lung Transplantation (2020) (17)
Effect of targeted disruption of signal transducer and activator of transcription (Stat)4 and Stat6 genes on the autoimmune diabetes development induced by multiple low doses of streptozotocin. (2005) (17)
CNS activity of Pokeweed Anti-viral Protein (PAP) in mice infected with Lymphocytic Choriomeningitis Virus (LCMV) (2005) (17)
Contraceptive activity of a spermicidal aryl phosphate derivative of bromo-methoxy-zidovudine (compound WHI-07) in rabbits. (2003) (17)
Developmental hierarchy during early human B-cell ontogeny after autologous bone marrow transplantation using autografts depleted of CD19+ B-cell precursors by an anti-CD19 pan-B-cell immunotoxin containing pokeweed antiviral protein (1992) (17)
Reactive oxygen intermediates activate NF-kappa B in a tyrosine kinase-dependent mechanism and in combination with vanadate activate the p56lck and p59fyn tyrosine kinases in human lymphocytes. (1993) (17)
Alpha-cyano-beta-hydroxy-beta-methyl-N-[4-(trifluoromethoxy)phenyl] propenamide: an inhibitor of the epidermal growth factor receptor tyrosine kinase with potent cytotoxic activity against breast cancer cells. (1998) (17)
Evaluation of subchronic (13‐week) and reproductive toxicity potential of intravaginal gel–microemulsion formulation of a dual‐function phenyl phosphate derivative of bromo‐methoxy zidovudine (compound whi‐07) in B6C3F1 mice (2000) (17)
In vitro and in vivo chemosensitizing activity of LFM-A13, a dual-function inhibitor of Bruton's tyrosine kinase and polo-like kinases, against human leukemic B-cell precursors (2011) (17)
Rejuveinix Shows a Favorable Clinical Safety Profile in Human Subjects and Exhibits Potent Preclinical Protective Activity in the Lipopolysaccharide-Galactosamine Mouse Model of Acute Respiratory Distress Syndrome and Multi‐Organ Failure (2020) (17)
Anti-inflammatory activity profile of JANEX-1 in preclinical animal models. (2008) (16)
Lipid Spheres as Attractive Nanoscale Drug Delivery Platforms for CancerTherapy (2011) (16)
Two-year toxicity and carcinogenicity studies in B(6)C(3)F(1) mice with 5-bromo-6-methoxy-5,6-dihydro-3'-azidothymidine-5'-(p-bromophenyl) methoxyalaninyl phosphate (WHI-07), a novel anti-HIV and contraceptive agent. (2002) (16)
Pharmacokinetics and biodistribution of radioimmunoconjugates of anti-CD19 antibody and single-chain Fv for treatment of human B-cell Malignancy (1998) (16)
A rationally designed nanoparticle for RNA interference therapy in B-lineage lymphoid malignancies (2014) (16)
Clinical Activity of Folinic Acid in Patients with Chronic Fatigue Syndrome (2006) (16)
The effects of aromatic and aliphatic maleimide crosslinkers on anti-CD5 ricin immunotoxins. (1989) (15)
Expression of biologically active recombinant pokeweed antiviral protein in methylotrophic yeast Pichia pastoris. (2000) (15)
Rational Design and Synthesis of a Novel Anti-leukemic Agent Targeting (1999) (15)
Structural influence on the anisotropic intermolecular hydrogen bonding in solid state of substituted thioureas: evidence by X-ray crystal structure (2004) (15)
Stampidine is a potential nonspermicidal broad-spectrum anti-human immunodeficiency virus microbicide. (2004) (15)
Apoptosis Inducing Novel Anti-Leukemic Agent, Bis(4,7-Dimethyl-1,10 Phenanthroline) Sulfatooxovanadium(IV)[VO(SO4)(Me2-Phen)2] Depolarizes Mitochondrial Membranes (2001) (15)
Zidampidine, an aryl phosphate derivative of AZT: in vivo pharmacokinetics, metabolism, toxicity, and anti-viral efficacy against hemorrhagic fever caused by Lassa virus. (2005) (15)
Radiation resistance of primary clonogenic blasts from children with acute lymphoblastic leukemia. (1993) (14)
Contemporary patient-tailored treatment strategies against high risk and relapsed or refractory multiple myeloma (2018) (14)
Generation and characterization of an anti-CD19 single-chain Fv immunotoxin composed of C-terminal disulfide-linked dgRTA. (1997) (14)
A Clinical Phase 1B Study of the CD3xCD123 Bispecific Antibody APVO436 in Patients with Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome (2021) (14)
Rational design of an immunoconjugate for selective knock-down of leukemia-specific E2A-PBX1 fusion gene expression in human Pre-B leukemia. (2013) (14)
Protease-mediated enzymatic hydrolysis and activation of aryl phosphoramidate derivatives of stavudine. (2005) (14)
CD22ΔE12 as a molecular target for RNAi therapy (2015) (14)
An improved method for cysteine alkylation (2001) (14)
Recombinant human CD19‐ligand protein as a potent anti‐leukaemic agent (2011) (14)
Production of recombinant DTctGMCSF fusion toxin in a baculovirus expression vector system for biotherapy of GMCSF-receptor positive hematologic malignancies. (1998) (14)
Interactions of Vanadocene(IV)-Chelated Complexes with Artificial Membranes (1998) (14)
Lipase-mediated stereoselective hydrolysis of stampidine and other phosphoramidate derivatives of stavudine. (2004) (13)
Bruton's tyrosine kinase as a new therapeutic target. (2007) (13)
Detection and characterization of human high molecular weight B cell growth factor receptors on leukemic B cells in chronic lymphocytic leukemia. (1989) (13)
X-Ray structure of glycerol kinase complexed with an ATP analog implies a novel mechanism for the ATP-dependent glycerol phosphorylation by glycerol kinase. (1999) (13)
Quantitative high-performance liquid chromatography-based detection method for calphostin C, a naturally occurring perylenequinone with potent antileukemic activity. (1999) (13)
In vitro Anti-HIV Potency of Stampidine Alone and in Combination with Standard Anti-HIV Drugs (2005) (13)
Quantitative high-performance liquid chromatographic method for pharmacokinetic studies of the potent mast cell inhibitor 4-(4'-hydroxyphenyl)amino-6,7-dimethoxyquinazoline (WHI-P131). (1999) (13)
SYK and LYN Mediate B-cell Receptor-independent Calcium-induced Apoptosis in DT-40 Lymphoma B-cells (2002) (13)
Prognostic significance of B-lineage leukemic cell growth in SCID mice: a Children's Cancer Group Study. (1998) (13)
CD22ΔE12 as a molecular target for corrective repair using RNA trans-splicing: anti-leukemic activity of a rationally designed RNA trans-splicing molecule. (2015) (13)
Structure-based design of potent inhibitors of EGF-receptor tyrosine kinase as anti-cancer agents. (1999) (13)
Development of Polypeptide-based Nanoparticles for Non-viral Delivery of CD22 RNA Trans-splicing Molecule as a New Precision Medicine Candidate Against B-lineage ALL (2015) (13)
Rational design and synthesis of phenethyl-5-bromopyridyl thiourea derivatives as potent non-nucleoside inhibitors of HIV reserve transcriptase. (1998) (12)
Phenyl phosphoramidate derivatives of stavudine as anti-HIV agents with potent and selective in-vitro antiviral activity against adenovirus. (2004) (12)
Mucosal safety of PHI-443 and stampidine as a combination microbicide to prevent genital transmission of HIV-1. (2007) (12)
Stampidine: a selective oculo-genital microbicide. (2005) (12)
In vivo Toxicity, Pharmacokinetic Features and Tissue Distribution of N-[2-(2,5-Dimethoxyphenylethyl)]-N’-[2-(5-bromopyridyl)]-thiourea (HI-236), a Potent Non-nucleoside Inhibitor of HIV-1 Reverse Transcriptase (2001) (12)
Synthesis and metabolism of naphthyl substituted phosphoramidate derivatives of stavudine. (2006) (12)
Incidence and biological significance of IKZF1/Ikaros gene deletions in pediatric Philadelphia chromosome negative and Philadelphia chromosome positive B-cell precursor acute lymphoblastic leukemia (2013) (12)
SPIKET and COBRA compounds as novel tubulin modulators with potent anticancer activity. (2000) (12)
Subchronic (13-week) toxicity studies of intravaginal administration of spermicidal vanadocene acetylacetonato monotriflate in mice. (2002) (12)
Phase I Study of B43-PAP Immunotoxin in Combination with Standard 4-Drug Induction for Patients with CD 19+ Acute Lymphoblastic Leukemia (ALL) in Relapse, A Children's Cancer Group Study (1999) (12)
Pharmacokinetics and Biologic Activity of the Novel Mast Cell Inhibitor, 4-(3′-Hydroxyphenyl)-amino-6,7-dimethoxyquinazoline in Mice (2004) (12)
In vivo Toxicity and Antithrombotic Profile of the Oral Formulation of the Antileukemic Agent, LFM-A13-F (2004) (12)
Targeting Janus kinase 3 in the treatment of leukemia and inflammatory diseases. (2004) (12)
Stampidine prevents mortality in an experimental mouse model of viral hemorrhagic fever caused by lassa virus (2004) (12)
A Dual Function Anti-leukemic Agent with Anti-thrombotic Activity (2002) (11)
Inhibition of mast cell leukotriene release by thiourea derivatives. (2003) (11)
Effect of alkyl groups on the cellular hydrolysis of stavudine phosphoramidates. (2006) (11)
CD19-antigen specific nanoscale liposomal formulation of a SYK P-site inhibitor causes apoptotic destruction of human B-precursor leukemia cells. (2014) (11)
Granulocyte-macrophage colony-stimulating factor receptor-targeted therapy of chemotherapy- and radiation-resistant human myeloid leukemias. (1997) (11)
Stereoselective synthesis of a versatile intermediate for the total synthesis of mono- and bis-THF containing annonaceous acetogenins (1999) (11)
COBRA-1, a rationally-designed epoxy-THF containing compound with potent tubulin depolymerizing activity as a novel anticancer agent. (2000) (11)
Rational drug design of multifunctional phosphoramidate substituted nucleoside analogs. (2004) (11)
A novel vaginal microbicide containing the rationally designed anti-HIV compound HI-443 (N′-[2-(2-thiophene)ethyl]-N′-[2-(5-bromopyridyl)] thiourea]) (2012) (11)
CYP1A-mediated metabolism of the Janus kinase-3 inhibitor 4-(4'-hydroxyphenyl)-amino-6,7-dimethoxyquinazoline: structural basis for inactivation by regioselective O-demethylation. (2002) (11)
Targeting JAK3 and BTK tyrosine kinases with rationally-designed inhibitors. (2006) (11)
Augmentation of the Antileukemia Potency of Total-Body Irradiation (TBI) by a Novel P-site Inhibitor of Spleen Tyrosine Kinase (SYK) (2010) (10)
Therapeutic potential of inhibiting Bruton's tyrosine kinase, (BTK). (2004) (10)
The anti-leukemic Bruton's tyrosine kinase inhibitor alpha-cyano-beta-hydroxy-beta-methyl-N-(2,5-dibromophenyl) propenamide (LFM-A13) prevents fatal thromboembolism. (2003) (10)
Protein kinase inhibitors against malignant lymphoma (2013) (10)
Stereochemistry as a Determinant of the Anti-Leukemic Potency of Halopyridyl and Thiazolyl Thiourea Compounds (2007) (10)
Synthesis of Symmetrical and Asymmetrical Phenethyl Thiourea Compounds as Nonnucleoside Inhibitors of HIV‐1 Reverse Transcriptase (2005) (10)
Structural influence on the intermolecular/intramolecular hydrogen bonding in solid state of substituted leflunomides : evidence by X-ray crystal structure (2005) (10)
Erratum to: Stampidine prevents mortality in an experimental mouse model of viral hemorrhagic fever caused by lassa virus (2004) (10)
Liposomal Nanoparticles of a Spleen Tyrosine Kinase P-Site Inhibitor Amplify the Potency of Low Dose Total Body Irradiation Against Aggressive B-Precursor Leukemia and Yield Superior Survival Outcomes in Mice☆ (2015) (9)
Piperidinylethyl, Phenoxyethyl and Fluoroethyl Bromopyridyl Thiourea Compounds with Potent Anti-HIV Activity (2000) (9)
IGF 1 Receptor Targeted Theranostic Nanoparticles for Targeted and Image-Guided Therapy of Pancreatic Cancer (9)
Regiospecific Synthesis of 5‐Halo‐substituted Thiophene Pyridyl Thiourea Compounds as Non‐nucleoside Inhibitors of HIV‐1 Reverse Transcriptase (2004) (9)
Effect of change in nucleoside structure on the activation and antiviral activity of phosphoramidate derivatives. (2005) (9)
A rationally designed anticancer drug targeting a unique binding cavity of tubulin. (2000) (9)
Antileukemic Activity and Cellular Metabolism of the Aryl Phosphate Derivative of Bromo-Methoxy Zidovudine (Compound WHI-07) (2005) (9)
Treatment of BCL-1 murine B-cell leukemia with recombinant cytokines. Comparative analysis of the anti-leukemic potential of interleukin 1 beta (IL-1 beta), interleukin 2 (IL-2), interleukin-6 (IL-6), tumor necrosis factor alpha (TNF alpha), granulocyte colony stimulating factor (G-CSF), granulocyte (1992) (9)
Inhibitor of HIV-1 reverse transcriptase: N'-(5-bromo-2-pyridyl)-N-[2-(2,5-dimethoxyphenyl)ethyl]thiourea. (1999) (9)
Stampidine as a promising antiretroviral drug candidate for pre-exposure prophylaxis against sexually transmitted HIV/AIDS (2012) (9)
Therapeutic nanoparticle constructs of a JAK3 tyrosine kinase inhibitor against human B-lineage ALL cells (2010) (9)
A Previously Unknown Unique Challenge for Inhibitors of SYK ATP-Binding Site: Role of SYK as A Cell Cycle Checkpoint Regulator (2014) (9)
Cysteine chloromethyl and diazomethyl ketone derivatives with potent anti-leukemic activity. (2000) (9)
Therapeutic innovations against HIV (2006) (9)
Allogeneic and autologous bone marrow transplantation for high risk acute lymphoblastic leukemia. (1992) (9)
Unmet Challenges in HIV Therapy and Potential of Stampidine (2006) (8)
In vivo Pharmacokinetics and Toxicity Profile of the Anti-HIV Agent Stampidine in Dogs and Feline Immunodeficiency Virus-infected Cats (2006) (8)
Clinical Potential of Targeting Bruton's Tyrosine Kinase (2008) (8)
N'-[2-(2-Thiophene)ethyl]-N'-[2-(5-bromopyridyl)]thiourea (HI-443), a Rationally Designed Non-Nucleoside Reverse Transcriptase Inhibitor Compound with Potent Anti-HIV Activity (2007) (8)
Targeting Solid Tumors With BTK Inhibitors (2021) (8)
Evaluation of the Pharmacokinetic Features and Tissue Distribution of the Potent Nonnucleoside Inhibitor of HIV-1 Reverse Transcriptase, N-[2-(2-fluorophenethyl)]-N′-[2-(5-bromopyridyl)]-thiourea (HI-240) with an Analytical HPLC Method (1999) (8)
In vivo radiosensitizing effects of recombinant interleukin 6 on radiation resistant BCL-1 B-lineage leukemia cells in a murine syngeneic bone marrow transplant model system. (1995) (8)
Paucity of leukemic progenitor cells in the bone marrow of pediatric B-lineage acute lymphoblastic leukemia patients with an isolated extramedullary first relapse. (1999) (8)
Crystal structure of Bruton's tyrosine kinase domain (2002) (8)
Low Dose Total Body Irradiation Combined With Recombinant CD19-Ligand × Soluble TRAIL Fusion Protein is Highly Effective Against Radiation-resistant B-precursor Acute Lymphoblastic Leukemia in Mice (2015) (8)
Primary blasts from infants with acute lymphoblastic leukemia cause overt leukemia in SCID mice. (1998) (8)
In vivo evaluation of a gel formulation of stampidine, a novel nonspermicidal broad-spectrum anti-HIV microbicide (2003) (8)
Reactivity of 1,4-didehydronaphthalene toward organic hydrogen atom donors (2000) (8)
A comparative study of the hydrolysis pathways of substituted aryl phosphoramidate versus aryl thiophosphoramidate derivatives of stavudine. (2004) (8)
In Vivo Pharmacokinetics and Anti-Anaphylactic Activity of the Novel Mast Cell Inhibitor 4-(4´-Hydroxylphenyl)-Amino-6,7-Dimethoxyquinazoline (WHI-P131) (2001) (8)
Introduction of a Carbohydrate Moiety into the Structure of Thiourea Compounds Targeting HIV-1 Reverse Transcriptase (2003) (8)
Tyrosine kinase inhibitors against EGF receptor-positive malignancies. (2001) (8)
In Vivo Treatment with Monoclonal Antibodies Directed Against CD4 and CD8 Antigens in Miniature Swine (1994) (7)
Specificity of α-Cyano-β-Hydroxy-β-Methyl-N-[4-(Trifluoromethoxy)Phenyl]-Propenamide as an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase (1999) (7)
Stereocontrolled synthesis of the tetrahydrofuran unit of annonaceous acetogenins (1998) (7)
The S-alkyl chain length as a determinant of the anti-leukemic activity of cysteine chloromethyl ketone compounds. (2000) (7)
Anti-retroviral Activity of GMP-Grade Stampidine against Genotypically and Phenotypically Nucleoside Reverse Transcriptase Inhibitor Resistant Recombinant Human Immunodeficiency Virus (2007) (7)
Developmental toxicology studies of WHI-07, a novel nucleoside analogue-based dual-function microbicide, administered intravaginally to rabbits. (2003) (7)
Cell-type-specific cytotoxicity of anti-CD4 and anti-CD8 ricin immunotoxins against human alloreactive T-cell clones. (1989) (7)
Targeting Mantle Cell Lymphoma with Anti-SYK Nanoparticles. (2012) (7)
Preclinical Toxicity and Pharmacokinetics of the Bruton's Tyrosine Kinase-Targeting Anti-leukemic Drug Candidate, α-Cyano-β-Hydroxy-β-Methyl-N-(2,5-Dibromophenyl) Propenamide (LFM-A13) (2007) (7)
mAbs targeting CD20 and other lymphocyte CD markers in lymphoma treatment (2013) (7)
Residual bone marrow leukemic progenitor cell burden after induction chemotherapy in pediatric patients with acute lymphoblastic leukemia. (2000) (7)
Selectively targeting TGF-β with Trabedersen/OT-101 in treatment of evolving and mild ards inCOVID-19 (2020) (7)
Constitutive Function of the Ikaros Transcription Factor in Primary Leukemia Cells from Pediatric Newly Diagnosed High-Risk and Relapsed B-precursor ALL Patients (2013) (7)
Targeting TGF-b pathway with COVID-19 Drug Candidate ARTIVeda/PulmoHeal Accelerates Recovery from Mild-Moderate COVID-19 (2021) (7)
Novel monoclonal antibody-based therapies for leukemia (2013) (7)
Effect of Targeting Janus Kinase 3 on the Development of Intestinal Tumors in the Adenomatous Polyposis Colimin Mouse Model of Familial Adenomatous Polyposis (2007) (7)
Potency of Stampidine Against Multi-Nucleoside Reverse Transcriptase Inhibitor Resistant Human Immunodeficiency Viruses (2006) (7)
Absence of Genomic Ikaros/IKZF1 Deletions in Pediatric B-Precursor Acute Lymphoblastic Leukemia. (2013) (7)
Leflunomide metabolite analogue alpha-cyano-beta-hydroxy-beta-methyl-N-[3-(trifluoromethyl)phenyl]propenamide inhibits IgE/FcepsilonRI receptor-mediated mast cell leukotriene release and allergic asthma in mice. (2001) (7)
High Resolution X-Ray Structure and Potent Anti-HIV Activity of Recombinant Dianthin Antiviral Protein (2004) (7)
CD5 antigen-positive B lymphocytes in human B cell ontogeny during fetal development and after autologous bone marrow transplantation. (1993) (7)
Clinical impact potential of Rejuveinix (RJX) for prevention of fatal acute respiratory distress syndrome (ARDS) and multi-organ failure in COVID-19 patients. (2020) (6)
Augmentation of Mast Cell Bactericidal Activity by the Anti-leukemic Drug, 4-(3'bromo-4'-hydroxylphenyl)-amino-6,7-dimethoxyquinazoline (2002) (6)
Bone Marrow Leukemic Progenitor Cell Content in Pediatric T-Lineage Acute Lymphoblastic Leukemia Patients with an Isolated Extramedullar First Relapse (2001) (6)
A 13-Week Subchronic Intravaginal Toxicity Study of the Novel Broad-Spectrum Anti-HIV and Spermicidal Agent, N-[2-(1-cyclohexenyl)ethyl]-N'-[2-(5-bromopyridyl)]-thiourea (PHI-346) in Mice (2002) (6)
Sensitivity of primary clonogenic blasts from acute lymphoblastic leukemia patients to an activated cyclophosphamide, viz., mafosfamide. (1994) (6)
Anti-cancer Activity Profile of 3’-Azidothymidine 5’- [p-Methoxyphenyl Methoxyalaninyl Phosphate] (Compound 003), a Novel Nucleoside Analog (2004) (6)
Stampidine as a potent epigenetic silencer of host HIV dependency factor genes in HIV-infected cells. (2012) (6)
Influence of long-term stability conditions on microbicidal nucleoside prodrug (WHI-07)-loaded gel-microemulsion (2006) (6)
Expression of a Unique Helios Isoform in Human Leukemia Cells (2002) (6)
Large-Scale Synthesis and Formulation of GMP-Grade Stampidine, a New Anti-HIV Agent (2006) (6)
N′-[2-(2-Thiophene)ethyl]-N′-[2′-(5-bromopyridyl)]-thiourea as a Potent Inhibitor of NNI-Resistant and Multidrug-Resistant Human Immunodeficiency Virus-1. (2000) (6)
A QUANTITATIVE HPLC DETECTION METHOD FOR WHI-P154 [4-(3′-BROMO-4′-HYDROXYLPHENYL)-AMINO-6,7-DIMETHOXYQUINAZOLINE] (1999) (6)
Dual Targeting of Multiple Myeloma Stem Cells and Myeloid-Derived Suppressor Cells for Treatment of Chemotherapy-Resistant Multiple Myeloma (2021) (6)
Optimization of conditions for formation and analysis of anti-CD19 FVS191 single-chain Fv homodimer (scFv')2. (1997) (6)
Rationale for a randomized, placebo-controlled, Phase 2 study of Rejuveinix (RJX) in COVID-19 patients with acute lung injury and hypoxemic respiratory failure (2020) (6)
Antigen-independent regulation of cytoplasmic calcium in B cells with a 12-kDa B-cell growth factor and anti-CD 19 ( B-cell activation / signal transduction / indo-1 / leukemic progenitor cells ) (6)
Identification and targeting of CD22ΔE12 as a molecular RNAi target to overcome drug resistance in high-risk B-lineage leukemias and lymphomas (2018) (6)
IGF-1 receptor targeted nanoparticles for image-guided therapy of stroma-rich and drug resistant human cancer (2016) (6)
Evaluation of local tolerance of the antiretroviral spermicide (WHI‐07)‐loaded gel‐microemulsion in the porcine female reproductive tract (2008) (6)
Impact of Therapy in Patients with Hematologic Malignancies on Seroconversion Rates After SARS-CoV-2 Vaccination (2022) (6)
Synthesis of β‐Fluorophenethyl Halopyridyl Thiourea Compounds as Non‐nucleoside Inhibitors of HIV‐1 Reverse Transcriptase (2004) (6)
Stat3-Syk Molecular Complex as A Target for Anti-Cancer Nanomedicines (2012) (5)
Three leflunomide metabolite analogs. (2000) (5)
4-[3-Bromo-4-hydroxyphenyl)amino]-6,7-dimethoxyquinazolin-1-ium chloride methanol solvate and 4-[(3-hydroxyphenyl)amino]-6,7-dimethoxy-1-quinazolinium chloride. (2001) (5)
Distinct in vivo engraftment and growth patterns of t(1;19)+/E2A-PBX1+ and t(9;22)+/BCR-ABL+ human leukemia cells in SCID mice. (1998) (5)
Development and Evaluation of a Thermoreversible Ovule Formulation of Stampidine, a Novel Nonspermicidal Broad-Spectrum Anti-HIV Microbicide (2003) (5)
Bone marrow augmentation of kidney allografts can cause graft-versus-host disease in immunosuppressed recipients. (1996) (5)
Allogeneic and autologous bone marrow transplantation for acute lymphoblastic leukemia. (1990) (5)
Bone marrow purging with immunotoxins for treatment of T cell acute lymphoblastic leukemia (T-ALL). (1990) (5)
In vivo Pharmacokinetics, Metabolism, Toxicity, and Anti-HIV Activity of N'-[2-(2-Thiophene)ethyl]-N'-[2-(5-bromopyridyl)]thiourea (HI-443), a Potent Non-nucleoside Inhibitor of HIV Reverse Transcriptase (2007) (5)
Anti-Inflammatory Activity of 2,4,6-Trihydroxy-α-p-Methoxyphenyl- acetophenone (Compound D-58) (2000) (5)
Synthesis of a Piceatannol Analog: Replacement of Hydroxy Group with Amide Functionality (2004) (5)
Stimulation of Bruton's Tyrosine Kinase (BTK) and Inositol 1,4,5-Trisphosphate Production in Leukemia and Lymphoma Cells Exposed to Low Energy Electromagnetic Fields (2000) (5)
Bis(4,7‐dimethyl and 5‐dinitro‐1,10‐phenanthroline) sulfato‐oxovanadium(IV)‐mediated in vivo male germ cell apoptosis (2001) (4)
Preclinical toxicity and pharmacokinetics of the Bruton's tyrosine kinase-targeting anti-leukemic drug candidate, alpha-cyano-beta-hydroxy-beta-methyl-N- (2,5-dibromophenyl) propenamide (LFM-A13). (2007) (4)
Recent advances in anogenital antiretroviral microbicides and multimodal delivery systems. (2012) (4)
Effects of Recombinant Interleukin‐3 and Recombinant Interleukin‐6 on Radiation Survival of Normal Human Bone Marrow Progenitor Cells (1993) (4)
Apoptosis-inducing vanadium complexes (2000) (4)
Recent advances in JAK3 kinase inhibitors. (1999) (4)
Aryl phosphate derivatives of 3'-deoxythymidine are not potent anti-human immunodeficiency virus agents. (1998) (4)
Rejection of the colon versus ileum in a pig model of total bowel transplantation. (1996) (4)
Stampidine: A potential nonspermicidal broad-spectrum anti-HIV microbicide (2003) (4)
Prevention of UVB-induced skin inflammation, genotoxicity, and photocarcinogenesis in mice by WHI-P131, a dual-function inhibitor of Janus kinase 3 and EGF receptor kinase (2010) (4)
Anti-proliferative and anti-leukemic activity of DDE46 (compound WHI-07), a novel bromomethoxylated arylphosphate derivative of zidovudine, and related compounds. Studies using human acute lymphoblastic leukemia cells and the zebrafish model. (2005) (4)
Safety, feasibility and preliminary efficacy of single agent combretastatin A1 diphosphate (OXi4503) in patients with relapsed or refractory acute myeloid leukemia or myelodysplastic syndromes (2020) (4)
Risk, Characteristics and Biomarkers of Cytokine Release Syndrome in Patients with Relapsed/Refractory AML or MDS Treated with CD3xCD123 Bispecific Antibody APVO436 (2021) (4)
Five analogs of the active metabolite of leflunomide (1999) (3)
Prevention of DMBA-induced mammary gland tumors in mice by a dual-function inhibitor of JAK3 and EGF receptor tyrosine kinases (2020) (3)
Nanoscale Small Interfering RNA Delivery Systems For Personalized Cancer Therapy Research Article (2012) (3)
Chemoprevention of Colorectal Cancer by Targeting Janus Kinase 3 With a Rationally Designed Small Molecule Inhibitor (2010) (3)
Recombinant human CD 19 L-sTRAIL effectively targets B cell precursor acute lymphoblastic leukemia (3)
Improved Oral Bioavailability of Anti-HIV Agent N'-[2-(2-Thiophene)ethyl]-NT-[2-(5-bromopyridyl)]-thiourea (HI-443) in a Novel Lipophilic Formulation (2007) (3)
Enzymatic hydrolysis of stampidine and other stavudine phosphoramidates in the presence of mammalian proteases. (2005) (3)
N‐[2‐(1‐Cyclohexenyl)ethyl]‐N′‐[2‐(5‐bromopyridyl)]‐thiourea and N′‐[2‐(1‐Cyclohexenyl)ethyl]‐N′‐[2‐(5‐chloropyridyl)]‐thiourea as Potent Inhibitors of Multidrug‐Resistant Human Immunodeficiency Virus‐1. (2010) (3)
Preclinical and clinical profile of Emmelle (dextrin-2-sulfate) -- a potential anti-HIV microbicide. (2005) (3)
Anti-prostate cancer activity of a nanoformulation of the spleen tyrosine kinase (SYK) inhibitor C61 (2020) (3)
siRNA Carrying Targeted Nanoparticles as a New Class of Rationally- Designed Anti-Cancer Therapeutics (2012) (3)
Targeting leukemic stem cells with multifunctional bioactive polypeptide nanoparticles. (2015) (3)
Specificity of a -Cyano- b -Hydroxy- b -Methyl- N -[4-(Trifluoromethoxy)Phenyl]-Propenamide as an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase (1999) (3)
Anti-inflammatory activity of 2,4, 6-trihydroxy-alpha-p-methoxyphenyl-acetophenone (compound D-58). (2000) (3)
CD123-Directed Bispecific Antibodies for Targeting MDS Clones and Immunosuppressive Myeloid-Derived Suppressor Cells (MDSC) in High-Risk Adult MDS Patients (2021) (3)
Nanoscale Small Interfering RNA Delivery Systems For Personalized Cancer Therapy Research Article (2012) (3)
Large-scale Synthesis of GMP Grade N'-[2-(2-Thiophene)ethyl]-N'-[2-(5-bromopyridyl)]-thiourea (HI-443), a New Anti-HIV Drug Candidate (2007) (2)
A Rationally Designed Anticancer Drug Targeting a Unique Binding Cavity of Tubulin (2000) (2)
Alpha-cyano-N-(2,5-dibromophenyl)-beta-hydroxybut-2-enamide. (1999) (2)
Heterogeneity in leukemia cell populations: A clear rationale for use of combination protocols for ex vivo marrow purging (1985) (2)
Treating severe COVID-19 in cancer patients (2020) (2)
Role of PRKCM (PKCμ) in Radiation-Induced Increase of JUN Proto-oncogene mRNA Levels in B-Lineage Lymphoid Cells (2000) (2)
Ex vivo elimination of neoplastic T-cells from human marrow using an anti-Mr 41,000 protein immunotoxin: Potentiation by ASTA Z 7557 (2004) (2)
Effects of recombinant human granulocyte-macrophage colony stimulating factor (rhgm-CSF) on radiation survival of normal human bone marrow progenitor cells (1987) (2)
An Improved Method for Cysteine Alkylation. (2001) (2)
Genomic Studies of the Spleen Protein Tyrosine Kinase Locus Reveal a Complex Promoter Structure and Several Genetic Variants (2002) (2)
ATIM-06. TREATMENT OF RECURRENT/REFRACTORY (R/R) ANAPLASTIC ASTROCYTOMA (AA, WHO GRADE 3) PATIENTS WITH ANTI-TGFß2 RNA THERAPEUTIC OT-101 VERSUS TEMOZOLOMIDE IS ASSOCIATED WITH IMPROVED OVERALL SURVIVAL (2019) (2)
Developmental Safety Profile of the Anti-HIV Agent Stampidine in Rabbits (2006) (2)
229 Activation of caspases in human t-lineage leukemia cells treated with analogs of leflunomide metabolite (2004) (2)
Phenyl Phosphoramidate Derivatives of Stavudine as anti‐HIV Agents with Potent and Selective in‐vitro Antiviral Activity Against Adenovirus. (2004) (2)
2,4,6-Trihydroxy-&agr;-p-methoxyphenylacetophenone (Compound D-58) Is a Potent Inhibitor of Allergic Reactions (2001) (2)
An Inhibitor of Janus Kinase 3. 4-(4-Hydroxyphenylamino)-6,7-dimethoxyquinazolin-1-ium Chloride Methanol Solvate. (2001) (2)
anti‐Cancer Activity Profile of 3′‐Azidothymidine 5′‐[p‐Methoxyphenyl Methoxyalaninyl Phosphate] (Compound 003), a Novel Nucleoside Analogue. (2005) (2)
Non-clinical safety profile and pharmacodynamics of two formulations of the anti-sepsis drug candidate Rejuveinix (RJX). (2021) (2)
Developmental Toxicology Studies of WHI-07, a Novel Nucleoside Analogue-Based Dual-Function Microbicide, Administered Intravaginally to Rabbits (2003) (2)
Role of Defective RNA Processing in the Pathogenesis of Pediatric Diseases (2011) (2)
Role of Clinical Pharmacodynamics Studies in the Era of Precision Medicines Against Cancer (2018) (2)
Tyrosine kinases in KMT2A/MLL-rearranged acute leukemias as potential therapeutic targets to overcome cancer drug resistance (2022) (2)
Stampidine as a Novel Nucleoside Reverse Transcriptase Inhibitor with Potent Anti-HIV Activity (2006) (2)
Monoclonal Antibody (mAb)-Based Biotherapy Options for B-lineage Non- Hodgkin's Lymphoma (NHL) (2013) (2)
In silico Molecular Target Validation Demonstrates Transforming Growth Factor Beta 2 is Strongly Expressed in Pediatric Diffuse Intrinsic Pontine Glioma and Glioblastoma Multiforme (2019) (2)
In vivo Pharmacokinetics and Toxicity of a Novel Hydrophilic Oral Formulation of the Potent Non-Nucleoside Reverse Transcriptase Inhibitor Compound N'-[2-(2-Thiophene)ethyl]-N'-[2-(5-bromopyridyl)]-thiourea (HI-443) (2007) (2)
KU HAPLOINSUFFIENCY CAUSES A LYMPHOPROLIFERATIVE DISORDER OF IMMATURE T-CELL PRECURSORS DUE TO IKAROS MALFUNCTION. (2013) (2)
Stereocontrolled Synthesis of a Novel Pharmacophore of the Tubulin‐Depolymerizing Marine Natural Product Spongistatin. (2000) (2)
Cancer drug resistance in multiple myeloma (2022) (1)
Overcoming barriers impeding early access of children and adolescents with cancer to emerging new therapeutic platforms and precision medicines (2018) (1)
Synthesis, Separation and Anti-HIV Activity of Distereoisomers of N-[p-(4-Bromophenyl)-2',3'-didehydro-3'-deoxy-5'-thymidylyl]-L-alanine Methyl Ester (Stampidine) (2006) (1)
Novel Thiourea Compounds as Dual-Function Anti-HIV and Spermicidal Agents (2000) (1)
Regulation of Human B Cell Function (1988) (1)
Post-hoc Analysis of Pharmacodynamics and Single-Agent Activity of CD3xCD123 Bispecific Antibody APVO436 in Relapsed/Refractory AML and MDS Resistant to HMA or Venetoclax Plus HMA (2022) (1)
ERBB1/EGFR and JAK3 Tyrosine Kinases as Potential Therapeutic Targets in High-Risk Multiple Myeloma (2022) (1)
LOW TEMPERATURE STRUCTURE OF POKEWEED ANTIVIRAL PROTEIN COMPLEXED WITH ADENINE (1999) (1)
Synthesis of Heterocyclic Thiourea Compounds with Amino Acid Side Chain as Nonnucleoside Inhibitors of HIV‐1 Reverse Transcriptase. (2006) (1)
Supramolecular Self-Assembled Nanoparticles Mediate Oral Delivery of Therapeutic TNFa TNFa TNFa siRNA against Systemic Inflammation * * (2013) (1)
Data-Driven identification of chemopreventive agents for breast cancer (2020) (1)
Abstract 5029: OT-101/Chemotherapy- A novel mechanism of action (MOA) in glioblastoma immunization therapy (2019) (1)
B-precursor leukemia Nanoscale liposomal formulation of a SYK P-site inhibitor against (2013) (1)
Regulation of Human B Cell Growth (1989) (1)
Editorial [Hot Topic:Non-Receptor Tyrosine Kinases as Molecular Targets for Patient Tailored Cancer Therapy (Guest Editors: F.M. Uckun, A. Vassilev and H. Tibbles)] (2007) (1)
SCID Mouse Models of Human Leukemia and Lymphoma as Tools for New Agent Development (2002) (1)
Stereoselective Synthesis of a Versatile Intermediate for the Total Synthesis of Mono‐ and Bis‐THF Containing Annonaceous Acetogenins. (1999) (1)
X-ray structure, solution properties, and biological activity profile of vanadocene(IV) acetylacetonate complex,. (2001) (1)
Chemopreventive efficacy of stampidine in a murine breast cancer model (2020) (1)
Development and Characterization of Three Recombinant Single Chain Antibody Fragments ( scFvs ) Directed against the CD 19 Antigen 1 (2006) (1)
Introduction of a Carbohydrate Moiety into the Structure of Thiourea Compounds Targeting HIV‐1 Reverse Transcriptase. (2003) (1)
Targeting Human B-Precursor Acute Lymphoblastic Leukemia Cells with Recombinant Human CD19 Ligand (2010) (1)
Regulatory Reforms Offer Renewed Hope for Pediatric Cancer Patients Who are in Urgent Need for Therapeutic Innovations (2018) (1)
Non-receptor tyrosine kinases as molecular targets for patient tailored cancer therapy. (2007) (1)
Site-Specific Enzymatic Activation of the Anti-HIV Agent Stampidine (2006) (1)
PREVENTION OF ISLET ALLOGRAFT REJECTION IN DIABETIC MICE BY TARGETING JANUS KINASE 3 WITH 4‐(4'‐HYDROXYPHENYL)‐AMINO‐6,7 ‐ DIMETHOXYQUINAZOLINE (WHI‐P131).: Abstract# 1147 (2000) (1)
Interleukin 3 Stimulation Enhances Tyrosine Phosphorylation and Proliferative Activity of Human Fetal Thymocytes and Leukemic T-cell Precursors at Multiple Developmental Stages of T-cell Ontogeny (1992) (1)
Augmented Expression of the IL3RA/CD123 Gene in MLL/KMT2A-Rearranged Pediatric AML and Infant ALL (2022) (1)
Risk and Severity of Cytokine Release Syndrome in Patients with Relapsed/Refractory (R/R) AML or MDS Treated with CD3xCD123 Bispecific Antibody APVO436 (2021) (1)
EARLY DETECTION OF SUBTYPE-SPECIFIC HIV-1 INFECTION USING TRANSCRIPTOMES FROM HOST CELL RESPONSES (2010) (1)
In vitro and in vivo Pharmacokinetic Features and Metabolism of the Novel Cytotoxic Nucleoside Analog 3’-Azidothymidine 5’- [p-Methoxyphenyl Methoxyalaninyl Phosphate] (Compound 003) (2004) (1)
disease across the major histocompatibility barrier in mice Targeting Janus kinase 3 to attenuate the severity of acute graft-versus-host (2013) (1)
Organic Phenyl Arsonic Acid Compounds with Potent Antileukemic Activity (2003) (1)
Recombinant Human CD19 Ligand for Biotherapy of B-lineage Lymphoid Malignancies (2012) (1)
mAbs targeting RANKL in bone metastasis treatment (2013) (1)
Large‐Scale Synthesis of GMP Grade α‐Cyano‐β‐hydroxy‐β‐methyl‐N‐ (2,5‐dibromophenyl)propenamide (LFM‐A13), a New Anticancer Drug Candidate. (2007) (1)
Rejuveinix Reverses Severe Inflammatory Lung Damage in a Mouse Model of Fatal Sepsis (2021) (1)
Specificity of alpha-cyano-beta-hydroxy-beta-methyl-n-[4-(trifluoromethoxy)phe nyl]-propenamide as an inhibitor of the epidermal growth factor receptor tyrosine kinase. (1999) (1)
A Degradation Study of a Series of Chloromethyl and Diazomethyl Ketone Anti-leukemic Agents (2002) (1)
Large-scale Synthesis of GMP Grade α-Cyano-β-hydroxy-β-methyl-N-(2,5-dibromophenyl) propenamide (LFM-A13), a New Anti-cancer Drug Candidate (2007) (1)
Three Leflunomide Metabolite Analogues. (2001) (0)
Subject Index Vol. 201, 2000 (2000) (0)
allografts in a murine bone marrow transplantation model disease but spares the graft-versus-leukemia function of the bone marrow Janus kinase 3 inhibitor WHI-P131/JANEX-1 prevents graft-versus-host (2013) (0)
Non-clinical safety profile and pharmacodynamics of two formulations of the anti-sepsis drug candidate Rejuveinix (2021) (0)
Therapeuticnanop article constructs of aJ AK3t yrosine kinasei nhibitoragainst humanB-lineage ALL cells (2010) (0)
Two-year toxicity and carcinogenicity study of the aryl phosphate derivative of bromo-methoxy zidovudine (compound WHI-07), a novel dual-function microbicide (2002) (0)
392 Targeting janus kinase 3 with JANEX-1 to attenuate the severity of acute graft-versus-host disease across the major histocompatibility barrier in mice (2004) (0)
Role of Kinase Inhibitors in Treatment of Lymphoid Malignancies (2013) (0)
Leukemic T-cell Precursors from T-lineage All Patients Are Characterized by Profound Ku80 Deficiency as well as Functional IK Deficiency with Very Low Ikaros Target Gene Expression Levels (2013) (0)
Preparation of a nanoscale liposomal CD 22 ΔE 12-siRNA formulation (2015) (0)
recombinant granulocyte-macrophage CSF, and their combination recombinant granulocyte colony-stimulating factor (G-CSF), Comparative analysis of the in vivo radioprotective effects of (2013) (0)
Monoclonal Antibodies in Oncology (2013) (0)
Monotherapy of High-Grade Gliomas with a TGFβ2-Targeting RNA Therapeutic (2020) (0)
marrow purging complement and 4- hydroperoxycyclophosphamide for ex vivo bone monoclonal antibodies (BA-1/CD24, BA-2/CD9, and BA-3/CD10) plus B-lineage acute lymphoblastic leukemia using a cocktail of three Autologous bone marrow transplantation in high-risk remission (2011) (0)
HIGH RESOLUTION STRUCTURE OF RECOMBINANT DIANTHIN ANTIVIRAL PROTEIN-POTENT ANTI-HIV AGENT (2004) (0)
In vivo contraceptive activity of novel dual-function microbicides: aryl phosphate derivatives of bromo-methoxy zidovudine (compounds WHI-05 and WHI-07) (2002) (0)
Sustained Target Lesion Shrinkage and Favorable Survival Outcome in Radiation and Radio Chemotherapy Resistant High Grade Glioma Treated by Convection Enhanced Delivery of a TGFβ2-Targeting RNA Therapeutic (2020) (0)
Cysteine Chloromethyl and Diazomethyl Ketone Derivatives with Potent Antileukemic Activity. (2010) (0)
Study CD2+CD19+ Acute Lymphoblastic Leukemia: A Children's Cancer Group Clinical Features and Treatment Outcome of Children With Biphenotypic (2013) (0)
Differential effects of recombinant human granulocyte colony-stimulating factor (rhG-CSF) on the radiation sensitivity of normal versus leukemic bone marrow progenitor cell populations. (1997) (0)
Intronic CD22 Gene Mutations as A Pathogenic Mechanism of Human B-Precursor Leukemia (2010) (0)
Synthesis of β-Fluorophenethyl Halopyridyl Thiourea Compounds as Non-nucleoside Inhibitors of HIV-1 Reverse Transcriptase. (2004) (0)
Radioimmunotherapy confers extended survival to SCID mice challenged with therapy-refractory human pre-B acute lymphoblastic leukemia (1994) (0)
Contents Vol. 201, 2000 (2000) (0)
Abstract LB-365: Unfolded protein response regulator BIP/HSPA5 as a chemoresistance biomarker and molecular target in acute lymphoblastic leukemia (2011) (0)
Leflunomide Metabolite Analogue &agr;-Cyano-&bgr;-hydroxy-&bgr;-methyl-N-[3-(trifluoromethyl)phenyl] Propenamide Inhibits IgE/FcϵRI Receptor–Mediated Mast Cell Leukotriene Release and Allergic Asthma in Mice (2001) (0)
STRUCTURE OF POKEWEED ANTIVIRAL PROTEIN COMPLEXED WITH GUANINE (1999) (0)
Islet allograft survival in signal transducer and activator of transcription factor (STAT)4- and STAT6-deficient mice (2000) (0)
Stereocontrolled Synthesis of the Tetrahydrofuran Unit of Annonaceous Acetogenins. (1998) (0)
Regiospecific Synthesis of 5-Halo-Substituted Thiophene Pyridyl Thiourea Compounds as Non-nucleoside Inhibitors of HIV-1 Reverse Transcriptase. (2004) (0)
Structure‐Based Design of a Novel Synthetic Spiroketal Pyran as a Pharmacophore for the Marine Natural Product Spongistatin 1. (2000) (0)
Wilms’ tumor gene (WT1) is strongly expressed in high-risk subsets of pediatric acute lymphoblastic leukemia (2018) (0)
Prophylactic administration of a clinically safe low dose of the COVID-19 drug candidate Rejuveinix (RJX) effectively prevents fatal cytokine storm and mitigates inflammatory organ injury in a mouse model of sepsis (2021) (0)
New Leads for Personalized Medicine in Pediatrics: Targeting Syk for Treatment of Serious Pediatric Illnesses (2012) (0)
Prevention of development of type 1 diabetes in NOD mice by targeting janus kinase (JAK)3 with 4-(4'-hydroxyphenyl)-amino-6,7-dimethoxyquinazoline (WHI-P131) (2000) (0)
Synthesis of Substituted Heterocyclic Thiourea Compounds. (2008) (0)
ISLET ALLOGRAFT SURVIVAL IN SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION FACTOR (STAT)4‐ AND STAT6‐DEFICIENT MICE.: Abstract# 899 Poster Board #‐Session: P156‐III (2000) (0)
Rejuveinix Mitigates Sepsis-Associated Oxidative Stress in the Brain of Mice: Clinical Impact Potential in COVID-19 and Nervous System Disorders (2021) (0)
Radiobiologien! Features of Fresh Leukemic Bone Marrow Progenitor Cells in Acute Lymphoblastic Leukemia1 (2006) (0)
Acknowledgment to Referees for Dermatology (2000) (0)
CD22 Exon 12 Deletion as an Independent Predictor of Poor Treatment Outcomes in B-ALL (2023) (0)
Upregulated Expression of ErbB1 in Diffuse Large B-Cell Lymphoma as a Predictor of Poor Overall Survival Outcome (2023) (0)
Contraceptive activity of a spermicidal aryl phosphate derivative of bromo-methoxy zidovudine (compound WHI-05) in rabbits. (2011) (0)
Complexes organometalliques de vanadium (iv) a activite spermicide (1999) (0)
Reactivity of 1,4‐Didehydronaphthalene Toward Organic Hydrogen Atom Donors. (2000) (0)
ATIM-03. ANTI-TGFß2 RNA THERAPEUTIC OT-101 INDUCES DURABLE OBJECTIVE RESPONSES IN PATIENTS WITH RECURRENT/REFRACTORY (R/R) GLIOBLASTOMA MULTIFORME (GBM, WHO GRADE 4) OR ANAPLASTIC ASTROCYTOMA (AA, WHO GRADE 3) (2019) (0)
Immunotoxin Using Anti-CD 19 ( B 43 )-Pokeweed Antiviral Protein Combined Immunodeficient Mice and Successful Treatment Establishment of a Human t ( 4 ; 11 ) Leukemia in Severe Updated (2006) (0)
Cancer Group Childhood Acute Lymphoblastic Leukemia: A Report From the Children's Association of Chromosome Arm 9p Abnormalities With Adverse Risk in (2012) (0)
RESPONSE TO TRKA ET AL AND GREAVES ET AL (1999) (0)
In Vitro and in Vivo Cytotoxicity of an Anti-Osteosarcoma Immunotoxin Containing Pokeweed Antiviral Protein 1 (2006) (0)
Illinois CNST Annual Nanotechnology Workshop 2010 Lecture 5: Nanoparticles against B–lineage Acute Lymphoblastic Leukemia (2011) (0)
B- lineage non-Hodgkin's lymphoma cells against clonogenic B-lineage acute lymphoblastic leukemia as well as immunotoxins of human B-cell ontogeny and the efficacy of anti-CD40 Temporal association of CD40 antigen expression with discrete stages (2011) (0)
SARS-CoV-2 Vaccine Efficacy in Patients with Hematologic Malignancies: Practical Points for Further Research (2022) (0)
Anti-Proliferative and Anti-Leukemic Activity of DDE46 (Compound WHI-07), a Novel Bromomethoxylated Arylphos-phate Derivative of Zidovudine, and Related Compounds (2005) (0)
Abstract B67: Stroma breaking dual targeted theranostic nanoparticles for image-guided and targeted therapy of pancreatic cancer (2016) (0)
CD22ΔE12 as a Molecular Target for RNAi Therapy in Mantle Cell Lymphoma (2018) (0)
Role of Clinical Pharmacokinetics Studies in Contemporary Oncology Drug Development (2018) (0)
Targeting TGF-beta pathway with COVID-19 Drug Candidate ARTIVeda/PulmoHeal Accelerates Recovery from Mild-Moderate COVID-19 (2021) (0)
RJX Improves Wound Healing in Diabetic Rats (2022) (0)
Microbicides for the Prevention of HIV (2014) (0)
Signal Transduction Through the CD19 Receptor during Developmental Stages of Human B-cell Ontogeny* (2001) (0)
ATIM-10. CLINICAL PREDICTORS OF RESPONSE FOR RECURRENT/REFRACTORY GLIOBLASTOMA MULTIFORME (GBM) AND ANAPLASTIC ASTROCYTOMA (AA, WHO GRADE III) PATIENTS TREATED WITH THE ANTI-TGFß2 RNA THERAPEUTIC OT-101 (2019) (0)
human interleukin-1 Leukemic B-cell precursors constitutively express functional receptors for (2012) (0)
Synthesis of Substituted Terphenyl Derivatives (VIII) (2007) (0)
LOW TEMPERATURE COMPLEX OF POKEWEED ANTIVIRAL PROTEIN WITH PTEORIC ACID (1999) (0)
Five Analogues of the Active Metabolite of Leflunomide. (2000) (0)
CCDC 135712: Experimental Crystal Structure Determination (1999) (0)
Cancer Group Positive Acute Lymphoblastic Leukemia: A Report From the Children's Clinical Features and Treatment Outcome of Children With Myeloid Antigen (2012) (0)
Treatment of Childhood T-Lineage Acute Lymphoblastic (1998) (0)
1061 Tyrosine kinase inhibitor 2,4,6-trihydroxy-αp-methoxyphenylacetophenone (Compound D-58) Is a potent inhibitor of allergic and inflammatory reactions (2000) (0)
Monoclonal antibodies in contemporary cancer therapy (2013) (0)
Pokeweed Antiviral Protein as an Universal Virus Neutralizer (2002) (0)
Wmmunotoxins for Treatment of Leukemia and LvmDhoma J I (1995) (0)
Signal transducer and activator of transcription (STAT)4 deficiency, associated with impaired Th1 immune response, reduces sensitivity to multiple low-dose streptozotocin-induced diabetes in STAT4−/− mice (2000) (0)
Leveraging structure-based rational drug design and nanotechnology to destroy leukemic stem cells (2014) (0)
Conjugates of antiviral proteins of Pokeweed and monoclonal antibodies. (1990) (0)
Original research article Vaginal contraceptive activity of a chelated vanadocene (2005) (0)
RTID-04. CLINICAL POTENTIAL OF TARGETING TRANSFORMING GROWTH FACTOR BETA 2 WITH OT-101 FOR POST-RADIATION CONSOLIDATION IN DIFFUSE INTRINSIC PONTINE GLIOMA (2022) (0)
Synthesis of a Piceatannol Analogue: Replacement of Hydroxy Group with Amide Functionality. (2004) (0)
Nanoscale liposomal CD22ΔE12-siRNA formulation as a potent RNAi therapeutic against B-cell precursor acute lymphoblastic leukemia (2014) (0)
High Intra-Tumor Transforming Growth Factor Beta 2 Level as a Predictor of Poor Treatment Outcomes in Pediatric Diffuse Intrinsic Pontine Glioma (2023) (0)
Leukemic bone marrow progenitor cells from T-lineage acute lymphoblastic leukemia (ALL) patients are able to repair sublethal radiation damage (1987) (0)
Phenylarsonic Acid Compounds with Broad-Spectrum and Potent Cytotoxic Activity against Human Cancer Cells (2003) (0)
Proof of concept for the clinical utility of a convection enhanced delivery platform for immuno-oncology drugs against brain tumors (2019) (0)
HIGH RESOLUTION STRUCTURE OF RECOMBINANT DIANTHIN ANTIVIRAL PROTEIN-POTENT ANTI-HIV AGENT (COMPLEX WITH CYCLIC AMP) (2004) (0)
Cancer Group Childhood Acute Lymphoblastic Leukemia: A Report From the Children's Hypodiploidy With Less Than 45 Chromosomes Confers Adverse Risk in (2011) (0)
Chromosomal Fusion Transcript Expression in the MLL-AF 4 Clinical Significance of (1998) (0)
Evaluation of the potential of Rejuveinix plus dexamethasone against sepsis (2022) (0)
Large-scale synthesis of GMP grade alpha-cyano-beta-hydroxy-beta-methyl-N-(2,5-dibromophenyl) propenamide (LFM-A13), a new anti-cancer drug candidate. (2007) (0)
1.6A CRYSTAL STRUCTURE OF POKEWEED ANTIVIRAL PROTEIN-III (PAP-III) WITH METHYLATED LYSINES (2003) (0)
344 JANEX-1, a novel anti-cancer agent with anti-thrombotic properties (2004) (0)
Leflunomide Metabolite Analogue -Cyano- -hydroxy- -methyl-N-[3-(trifluoromethyl)phenyl] Propenamide Inhibits IgE/Fc RI Receptor–Mediated Mast Cell Leukotriene Release and Allergic Asthma in Mice (2001) (0)
Aryl phosphate derivatives of d4t with anti-HIV effect (1999) (0)
LOW TEMPERATURE STRUCTURE OF POKEWEED ANTIVIRAL PROTEIN (1999) (0)
Clinical Potential of Combretastatin A1 Diphosphate for the Treatment of Relapsed Pediatric Acute Myeloid Leukemia (2019) (0)
Abnormalities o f C hromosome B ands 1 3q12 t o 1 3q14 i n Childhood A cute L ymphoblastic L eukemia (2000) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Fatih Mehmet Uckun?

Fatih Mehmet Uckun is affiliated with the following schools:

Fatih Mehmet Uckun's Academic­Influence.com Rankings

Fatih Mehmet Uckun's Degrees

Why Is Fatih Mehmet Uckun Influential?

Fatih Mehmet Uckun's Published Works

Published Works

What Schools Are Affiliated With Fatih Mehmet Uckun?

Fatih Mehmet Uckun's AcademicInfluence.com Rankings